Cardiff Oncology, Inc.CRDF

Cardiff Oncology filed an S-8 on 21 July to register 3.2 million shares for general corporate purposes , a disclosure that lands like a polite cough in a crowded oncology conference. The balance sheet for the quarter ending 31 March shows revenue of just $41,000, net loss of $12.3 million, and operating cash burn of $12.8 million, while cash and equivalents sit at $8.5 million and short-term investments total $37.5 million. The glossy product pages and clinical-trial graphics therefore read less like evidence and more like wishful fill. (source: CRDF S-8, 2026-07-21, https://www.sec.gov/Archives/edgar/data/1213037/000119312526310273/crdf-20260720.htm; 10-Q, 2026-03-31, https://www.sec.gov/Archives/edgar/data/1213037/000166470826000002/xslF345X06/ownership.xml)

Onvansertib is Cardiff’s lead asset , a highly selective PLK1 inhibitor positioned as a targeted therapy in metastatic colorectal cancer. The company’s pipeline page and ONSEMBLE mCRC programme state the drug is the only PLK1 inhibitor in development with activity against aggressive KRAS mutations, yet the peer-reviewed data from the Phase 2 portion of the CRDF-004 randomised trial was published on 30 October 2024 in the Journal of Clinical Oncology and remains behind a paywall. The product pages present a single ongoing trial as if it were a finished textbook, while the company simultaneously files shelf registrations to sell more shares. (source: Onvansertib Product Pipeline - Cardiff Oncology, https://cardiffoncology.com/pipeline/; ONSEMBLE mCRC - Cardiff Oncology, https://www.cardiffoncology.com/onsemble-mcrc/)

The filing binge continues : on 16 July Cardiff registered 3.2 million shares via a 424B5, the same day it posted ownership tables showing no change in director holdings since June. Diluted share count rose to 68.3 million, up roughly 4.7% in the quarter, while the cash balance is flattered by $37.5 million of short-term investments that do nothing for operating runway. Earnings per share came in at minus 18 cents on just $41,000 of revenue, a ratio that turns “clinical-stage” into a polite euphemism. Assets of $49.2 million are underpinned by $34.7 million of equity, but the burn rate suggests the runway is measured in single-digit months unless the next trial readout or partnership arrives pronto. (source: CRDF 424B5, 2026-07-16, https://www.sec.gov/Archives/edgar/data/1213037/000119312526305465/crdf_07.14.26_-_424b5.htm; 10-Q, 2026-03-31, https://www.sec.gov/Archives/edgar/data/1213037/000166470826000002/xslF345X06/ownership.xml)

For context on the company’s operating reality, the official site frames Cardiff as a “clinical-stage company with the singular mission of developing new oncology therapeutic options,” language that reads less like fact and more like a grant application. The pipeline graphic and product pages are sleek but carry no obligation to prove anything; the regulatory and commercial path remains hypothetical while the cash runway tightens. (source: Cardiff Oncology - Cardiff Oncology, https://cardiffoncology.com/; Cardiff Oncology - Cardiff Oncology, https://www.cardiffoncology.com/)

The SEC EDGAR index and submissions JSON confirm the filing cadence but offer no comfort on timing or magnitude of any future approval, revenue, or cash inflow. Until the next Phase 2 or Phase 3 readout-or a partnership that converts the science into sales-the gap between the polished platform story and the filed numbers stays both obvious and unbridgeable. (source: CRDF SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1213037; CRDF SEC submissions JSON, https://data.sec.gov/submissions/CIK0001213037.json)

For readers tracking the company’s clinical narrative, the CRDF-004 Phase 2 randomised trial in first-line RAS-mutated metastatic colorectal cancer produced initial results presented on 10 December 2024 and published online on 30 October 2024, but the peer-reviewed article sits behind a paywall and the trial is still enrolling. That leaves the company’s core asset story suspended between aspiration and evidence, with no public update on dose confirmation or efficacy beyond the initial headline. (source: CRDF-004 trial evidence, https://cardiffoncology.com/pipeline/)